

Sister Study Self-Reported and Medically Confirmed Cancer Estimates by Primary Site of Origin, Excluding Non-Melanoma Skin Cancer

Table 1: Data Release 10.1^{1,2}

	Prevalent		Unknown Timing		Incident				
	Diagnosis at or prior to baseline	Diagnosis date unknown	Not confirmed (Self-report without medical, NDI, or death certificate confirmation)		Confirmed by NDI or Death Certificate only (No medical confirmation)		Medically Confirmed		Total Incident
			N	%	N	%	N	%	N
Any Cancer (excluding NMSC)	4,446	246	1,783	22.9	302	3.9	5,696	73.2	7,781
Primary Site³									
Breast Cancer									
DCIS or invasive	59	17	683	15.9	45	1.0	3,564	83.0	4,292
LCIS	54	8	29	23.4	0	0.0	95	76.6	124
Reproductive Cancers									
Ovarian, fallopian tube, and peritoneal	204	30	67	22.9	35	12.0	190	65.1	292
Uterine (including endometrial)	381	55	98	23.4	20	4.8	301	71.8	419
Cervical	552	7	16	34.8	1	2.2	29	63.0	46
Vulvar	20	2	7	18.9	0	0.0	30	81.1	37
Vaginal	6	2	1	14.3	0	0.0	6	85.7	7
Digestive Cancers									
Colon and rectal (including appendiceal)	201	18	107	31.6	23	6.8	209	61.7	339
Small intestinal	5	0	5	41.7	3	25.0	4	33.3	12
Anal	8	1	9	25.7	1	2.9	25	71.4	35
Pancreatic	7	1	30	15.1	73	36.7	96	48.2	199
Biliary tract ⁴	1	0	10	21.7	13	28.3	23	50.0	46
Liver (including intrahepatic bile duct) ⁴	6	0	31	50.0	18	29.0	13	21.0	62
Stomach and esophageal	14	1	17	30.4	15	26.8	24	42.9	56
Endocrine Gland Cancers									
Thyroid	273	16	78	26.6	1	0.3	214	73.0	293
Lower Respiratory and Intrathoracic Cancers									
Bronchus and lung	65	3	149	25.8	146	25.3	283	49.0	578
Head and Neck Cancers									
Lip, oral cavity, pharynx, and upper respiratory tract	23	1	24	25.3	8	8.4	63	66.3	95
Urinary Cancers									
Kidney	61	0	41	26.1	5	3.2	111	70.7	157
Bladder	62	0	26	19.4	5	3.7	103	76.9	134
Renal pelvis, ureter, urethra	2	0	4	15.4	2	7.7	20	76.9	26

Abbreviations: DCIS=Ductal carcinoma *in situ*; LCIS=Lobular carcinoma *in situ*; NMSC=non-melanoma skin cancer

¹ Data release 10.1 includes events from follow-up phases that closed on or before 10/12/2020, excluding all data from participants who have withdrawn their data from the study (n=4)

² See Table 2 for approximated estimates for additional cancer outcomes

³ Includes all cancers that display invasive behavior (ICD-O-3 behavior code = /3), *in situ* behavior (ICD-O-3 behavior code = /2), or uncertain or borderline behavior (ICD-O-3 behavior code = /1). See specific ICD10 codes for each cancer type [here](#)

⁴ Intrahepatic bile duct cancer diagnoses are included in both biliary tract and liver cancer counts

Table 2: Approximates Data Release 10.1^{1,2}

Primary Site ³	Prevalent		Unknown Timing		Incident				Total Incident
	Diagnosis at or prior to baseline	Diagnosis date unknown	Not confirmed (Self-report without medical, NDI, or death certificate confirmation)		Confirmed by NDI or Death Certificate only (No medical confirmation)		Medically Confirmed		
	N	N	N	%	N	%	N	%	
Skin Cancers									
Melanoma of the skin	750	60	345	34.8	4	0.4	641	64.7	990
Lymphoid and Hematopoietic Cancers									
Non-Hodgkin's lymphoma	89	8	74	24.5	16	5.3	212	70.2	302
Hodgkin's lymphoma	27	9	9	50.0	3	16.7	6	33.3	18
Multiple myeloma	6	2	17	16.3	11	10.6	76	73.1	104
Leukemia	55	13	65	28.1	19	8.2	147	63.6	231
Myelodysplastic syndrome	3	0	13	31.7	7	17.1	21	51.2	41
Polycythemia vera	3	0	14	63.6	0	0.0	8	36.4	22
Brain and Other Central Nervous System Cancers									
Brain tumors (malignant and benign)	69	23	166	41.8	39	9.8	192	48.4	397
Eye and adnexa	9	2	9	75.0	0	0.0	3	25.0	12
Other central nervous system	1	3	7	100.0	0	0.0	0	0.0	7
Other and Unspecified Cancers									
Bone	13	2	36	80.0	1	2.2	8	17.8	45
Mesothelium and soft tissue	20	6	16	28.1	12	21.1	29	50.9	57
Gastrointestinal stromal tumor	4	0	8	32.0	0	0.0	17	68.0	25
Neuroendocrine	20	4	18	19.8	0	0.0	73	80.2	91
Any other cancer, specified or unspecified (excluding NMSC)	82	507	130	44.2	38	12.9	126	42.9	294

Abbreviation: NMSC=non-melanoma skin cancer

¹ Data release 10.1 includes events from follow-up phases that closed on or before 10/12/2020, excluding all data from participants who have withdrawn their data from the study (n=4)

² These baseline and self-reported estimates are likely an over-estimate of the actual number of cases

³ Includes all cancers that display invasive behavior (ICD-O-3 behavior code = /3), *in situ* behavior (ICD-O-3 behavior code = /2), or uncertain or borderline behavior (ICD-O-3 behavior code = /1). See specific ICD10 codes for each cancer type [here](#)